| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 189.717 | 182.610 | 192.610 | 200.839 | 220.309 | 251.210 | 273.560 | 292.560 | 313.974 | 319.520 |
| Total Income - EUR | 191.038 | 183.440 | 193.257 | 201.927 | 220.312 | 251.550 | 274.070 | 294.055 | 315.557 | 320.050 |
| Total Expenses - EUR | 180.205 | 174.827 | 186.965 | 196.964 | 217.349 | 241.985 | 260.663 | 282.054 | 305.805 | 310.815 |
| Gross Profit/Loss - EUR | 10.834 | 8.614 | 6.292 | 4.963 | 2.964 | 9.565 | 13.407 | 12.001 | 9.752 | 9.235 |
| Net Profit/Loss - EUR | 9.100 | 7.215 | 4.399 | 2.953 | 760 | 7.418 | 10.856 | 9.110 | 6.975 | 7.547 |
| Employees | 3 | 4 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 |
Check the financial reports for the company - Infinitti Farmacom Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 647 | 530 | 411 | 416 | 403 | 391 | 379 | 3 | 0 | 0 |
| Current Assets | 44.700 | 43.784 | 51.384 | 52.838 | 61.472 | 69.704 | 77.794 | 78.558 | 81.543 | 84.051 |
| Inventories | 18.600 | 24.549 | 22.825 | 17.470 | 25.996 | 30.270 | 28.810 | 31.528 | 32.669 | 38.114 |
| Receivables | 17.599 | 6.467 | 23.253 | 32.578 | 29.219 | 34.252 | 37.461 | 44.198 | 44.834 | 41.562 |
| Cash | 8.501 | 12.768 | 5.307 | 2.790 | 6.257 | 5.182 | 11.524 | 2.832 | 4.041 | 4.374 |
| Shareholders Funds | 9.191 | 7.305 | 4.487 | 3.040 | 846 | 7.503 | 10.939 | 9.193 | 9.065 | 9.324 |
| Social Capital | 49 | 49 | 48 | 47 | 46 | 45 | 44 | 45 | 44 | 44 |
| Debts | 36.156 | 37.008 | 47.308 | 50.213 | 61.029 | 62.592 | 67.234 | 69.368 | 72.479 | 74.727 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Infinitti Farmacom Srl